Background: Although the discovery of new biomarkers in atopic dermatitis (AD) is challenging, it is valuable in diagnosis, assessment of severity, and evaluation of treatment response.
Objective: This study was designed to identify and validate new candidate protein biomarkers of AD via proteomic analysis.
Methods: Comparison of protein expression in the patients' serum before- and after-treatment and in patients without AD was performed via two-dimensional gel electrophoresis (2-DE), followed by image analysis. Spots showing differential expression in 2-DE image analysis were identified subsequently via nanoscale liquid chromatography-tandem mass spectrometry (LC-MS/MS) experiments. Blood tests were conducted to validate the results obtained by measuring the levels of candidate proteins.
Results: Based on LC-MS/MS analysis and database search, we identified ceruloplasmin (Cp) as a candidate protein. Serum Cp levels were significantly decreased in in pre-treated AD group than in control group. Additionally, the serum Cp level was higher in the mild group than in the moderate group of AD based on the Eczema Area and Severity Index (EASI) score.
Conclusion: Low serum Cp levels are associated with AD, suggesting the potential role of Cp as a biomarker for diagnosis and severity assessment of AD.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9365656 | PMC |
| http://dx.doi.org/10.5021/ad.21.321 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
The Significant Role of Atopic Skin Diathesis in Prurigo Nodularis.
Sisli Etfal Hastan Tip Bul
December 2024
Department of Dermatology and Venereology, Istanbul Faculty of Medicine, Istanbul University, Istanbul, Türkiye.
Objectives: Atopic skin plays a significant etiological role in the development of prurigo nodularis (PN). In addition to atopic dermatitis (AD), atopic skin diathesis without eczema can also contribute to the development of PN due to its association with itching. This study aims to evaluate PN in terms of AD/atopic skin diathesis, associated comorbidities, and clinical findings.
View Article and Find Full Text PDFEfficacy of Rose Stem Cell-Derived Exosomes (RSCEs) in Skin Treatment: From Healing to Hyperpigmentation Management: Case Series and Review.
J Cosmet Dermatol
January 2025
Małopolska Centre of Biotechnology, Stem Cell Laboratory, Jagiellonian University, Kraków, Poland.
Objective: To present and analyze eight clinical cases illustrating the use of rose stem cell-derived exosomes (RSCEs) in treating various dermatological conditions and to review current literature on plant-derived exosomes in medicine and dermatology.
Background: RSCEs possess low cytotoxicity, high biocompatibility, and effective cellular uptake, making them promising agents for dermatological therapies. A literature review included in the introduction and discussion covers the broader role of plant-derived exosomes, highlighting their therapeutic potential in skin treatment.
Quality of Life in Adults with Atopic Dermatitis in Relation to Disease Severity: Nationwide Data in Japan.
Dermatol Ther (Heidelb)
January 2025
Medical Affairs, Otsuka Pharmaceutical Co., Ltd., Shinagawa Grand Central Tower, 2-16-4 Konan, Minato-ku, Tokyo, 108-8241, Japan.
Introduction: The impact of atopic dermatitis (AD) on daily life and different levels of quality of life (QOL) according to AD severity has not been fully elucidated. This study aimed to assess QOL in relation to the AD severity in Japan.
Methods: This observational study used anonymized data of health insurance association members and their families registered to a mobile health app.
Successful Achievement of Demanding Outcomes in Upadacitinib-Treated Atopic Dermatitis Patients: A Real-World, 96-Week Single-Centre Study.
Dermatol Ther (Heidelb)
January 2025
1st Department of Dermatology and Venereology, Medical School of Athens, Andreas Sygros Hospital, National and Kapodistrian University of Athens, Athens, Greece.
Introduction: Results from randomized controlled trials of upadacitinib, a Janus kinase (JAK) inhibitor, have led to its approval for the treatment of moderate-to-severe atopic dermatitis (AD) in patients aged ≥ 12 years. The aim of this study was to report the effectiveness and safety of upadacitinib in real-world settings over a period of 96 weeks.
Methods: This retrospective study included all patients treated with upadacitinib at our centre between April 2022 and September 2024.
Identifying Disease Associated Multi-Omics Network With Mixed Graphical Models Based on Markov Random Field Model.
Genet Epidemiol
January 2025
Interdisciplinary Program of Bioinformatics, College of Natural Science, Seoul National University, Seoul, South Korea.
In this article, we proposed a new method named fused mixed graphical model (FMGM), which can infer network structures associated with dichotomous phenotypes. FMGM is based on a pairwise Markov random field model, and statistical analyses including the proposed method were conducted to find biological markers and underlying network structures of the atopic dermatitis (AD) from multiomics data of 6-month-old infants. The performance of FMGM was evaluated with simulations by using synthetic datasets of power-law networks, showing that FMGM had superior performance for identifying the differences of the networks compared to the separate inference with the previous method, causalMGM (F1-scores 0.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!